X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Fremanezumab
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Ajovy
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2021
Details:
Combined review of Phase 3 studies with fremanezumab indicates positive cardiovascular safety profile in adult patients. Additional data on injection-related adverse reactions provide new guidance to healthcare professionals for the optimal selection of injection sites.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PLX-PAD
Therapeutic Area: Cardiology/Vascular Diseases Product Name: PLX-PAD
Highest Development Status: Phase III Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2020
Details:
Based on the review, the DMC concluded that the CLI study is unlikely to meet the primary endpoint by the time of the final analysis. Company to terminate the CLI study of PLX-PAD to focus on different therapeutic areas in its pipeline.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
